Therapeutic Area: Musculoskeletal
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Revance Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2020
Under the agreement Revance will gain immediate and exclusive rights to commercialize TEOXANE’s RHA® line of fillers in the U.S.